AMH as a Prognostic Factor for Blastocyst Development

Conto, Emily de; Genro, Vanessa Krebs; Silva, Daniela Scherer da; Chapon, Rita de Cassia Borges; Cunha-Filho, João Sabino

doi:10.5935/1518-0557.20150029

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latter group of women is similar to the population enrolled in our study, and hence the results may be considered to be in agreement (Lie Fong et al, 2008). Perhaps one of the most controversial findings in our study was that AMH levels correlated with embryo quality, as reported by De Conto et al (2015); however, since our population was small, the quality A blastocyst higher pregnancy rate was not significantly different. It should also be mentioned that some authors have described AMH as a weak predictor for clinical pregnancy, which may explain why we found no differences between pregnancy rates in our results (Tal et al, 2015;Umarsingh et al, 2020).…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Evaluation of the Anti-Müllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population

Morales¹,

López²,

Cortés³

et al. 2022

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective Serum anti-Müllerian hormone (AMH) presents a strong positive correlation with quantitative aspects of the ovarian reserve, while its correlation with embryo quality is unclear. This study assessed the association between serum AMH as a marker of ovarian reserve and embryo quality, in women undergoing in vitro fertilization. Methods This observational analytical retrospective study included patients seen between 2010 and 2018. In vitro fertilization patients with measured AMH levels were analyzed based on the following parameters: number of retrieved oocytes; number of metaphase II oocytes; embryo quality; and treatment outcome. Statistical analysis was performed using ANOVA, Mann-Whitney U test, linear regression, and Pearson and Spearman correlations. Results We found a positive correlation between AMH levels, number of retrieved oocytes and number of metaphase II oocytes (r 0.649, p =0.000). The numbers of retrieved and metaphase II oocytes were predicted in 42% (R2: 429) of the cases based on AMH levels ( p =0.000). Serum AMH levels were not associated with embryo quality on Day 3 ( p =0.151); an association was seen between AMH levels and embryo quality on Day 5 ( p =0.006). The distribution of AMH levels was the same across patients, regardless of whether they were able to achieve pregnancy ( p =0.767). Conclusions AMH levels correlated with embryo quality on Day 5; no association was found between AMH levels and embryo quality on Day 3 or pregnancy rate. The use of AMH levels to predict embryo quality still requires further studies; therefore, AMH should be used to assess the ovarian reserve only.

show abstract

Section: Discussionsupporting

confidence: 84%

“…Perhaps one of the most controversial findings in our study was that AMH levels correlated with embryo quality, as reported by De Conto et al . (2015) ; however, since our population was small, the quality A blastocyst higher pregnancy rate was not significantly different.…”

Section: Discussionmentioning

confidence: 47%

Evaluation of the Anti-Müllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population

Morales¹,

López²,

Cortés³

et al. 2022

JBRA Assisted Reproduction

View full text Add to dashboard Cite

show abstract

“…The difference in pregnancy outcomes among blastocyst groups may be related to serum AMH concentrations. Scheffer et al and De Conto et al showed that serum AMH concentration was related to embryo development and blastocyst formation, but too high or too low AMH concentration was not conducive to blastocyst formation (12,13). In our study, AMH in HQB-D5 was significantly higher than in LQB groups regardless of D5 or D6, suggesting that it was related to the quality of the blastocysts formed.…”

Section: Discussionsupporting

confidence: 42%

D6 high-quality expanded blastocysts and D5 expanded blastocysts have similar pregnancy and perinatal outcomes following single frozen blastocyst transfer

Hu,

Zheng,

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveWe compared the pregnancy and perinatal outcomes between expanded blastocysts vitrified on D5 versus D6 following single frozen blastocyst transfer.MethodsClinical data on 7,606 cycles of frozen-thawed blastocyst implantations were retrospectively analyzed. Depending on whether blastocysts were vitrified on D5 or D6 and the transferred blastocysts, the blastocysts were divided into 6 groups: HQB-D5, HQB-D6, 4XC-D5, 4XC-D6, 4CX-D5, and 4CX-D6 groups. The differences in clinical pregnancy rate, live birth rate, first trimester abortion rate, preterm birth rate, gestational age, birth weight, and sex ratio at birth among the groups were compared.ResultsOur study showed that there was no difference in pregnancy and perinatal outcomes between the delayed formation of D6 high-quality expanded blastocysts and D5 expanded blastocysts, whether they were high-quality blastocysts or not. For low-quality blastocysts, the clinical pregnancy rate of D5 was higher than that of D6, and D5 was also better than D6 in live birth rate for those with inner cell mass rating B or above, while there was no difference between D5 and D6 for those with inner cell mass rating C.ConclusionBased on our research, we suggest that when we are developing the implantation strategy, we give priority to the selection of high-quality expanded blastocysts, regardless of D5 and D6, whose clinical outcomes are not different. For low-quality blastocysts, D5 expanded blastocysts are preferred for transfer.

show abstract

“…AMH has been shown to predict oocyte morphology, fertilization, blastocyst formation, implantation, and pregnancy rates [5,19,20]. Borges et al (2017) found that, in a sample of 4488 oocytes from 408 patients, AMH was predictive of embryo morphology on day 2 and day 3, fertilization and blastocyst formation, implantation rates, and clinical pregnancy rates after adjusting for age [5].…”

Section: Introductionmentioning

confidence: 99%

AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles

Seifer

Tal

2023

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background While anti-Müllerian hormone (AMH) predicts quantitative IVF outcomes such as oocyte yield, it is not certain whether AMH predicts markers of oocyte quality such as aneuploidy. Methods Retrospective case–control analysis of the SART-CORS database, 2014–2016, to determine whether anti-Müllerian hormone (AMH) predicts aneuploidy and live birth in IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A). Results Of 51,273 cycles utilizing PGT-A for all embryos, 10,878 cycles were included in the final analysis; of these, 2,100 cycles resulted in canceled transfer due to lack of normal embryos and 8,778 cycles resulted in primary FET. AMH levels of cycles with ≥ 1 euploid embryo were greater than those of cycles with no normal embryos, stratifying by number of embryos biopsied (1–2, 3–4, 5–6, and ≥ 7), P < 0.017 for each stratum. Adjusting for age and number of embryos biopsied, AMH was a significant independent predictor of ≥ 1 euploid embryo for all age groups: < 35 yrs (aOR 1.074; 95%CI 1.005–1.163), 35–37 years (aOR 1.085; 95%CI 1.018–1.165) and ≥ 38 years (aOR 1.055; 95%CI 1.020–1.093). In comparative model analysis, AMH was superior to age as a predictor of ≥ 1 euploid embryo for age groups < 35 years and 35–37 years, but not ≥ 38 years. Across all cycles, age (aOR 0.945, 95% CI 0.935–0.956) and number of embryos (aOR 1.144, 95%CI 1.127–1.162) were associated with live birth per transfer, but AMH was not (aOR 0.995, 95%CI 0.983–1.008). In the subset of cycles resulting in ≥ 1 euploid embryo for transfer, neither age nor AMH were associated with live birth. Conclusions Adjusting for age and number of embryos biopsied, AMH independently predicted likelihood of obtaining ≥ 1 euploid embryo for transfer in IVF PGT-A cycles. However, neither age nor AMH were predictive of live birth once a euploid embryo was identified by PGT-A for transfer. This analysis suggests a predictive role of AMH for oocyte quality (aneuploidy risk), but not live birth per transfer once a euploid embryo is identified following PGT-A.

show abstract

AMH as a Prognostic Factor for Blastocyst Development

Abstract: We conclude that patients that were considered eligible to undergo blastocyst formation have higher levels of serum AMH, however too high concentration of this hormone can be harmful to blastocyst development.

Cited by 9 publications

References 17 publications

Evaluation of the Anti-Müllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population

Evaluation of the Anti-Müllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population

D6 high-quality expanded blastocysts and D5 expanded blastocysts have similar pregnancy and perinatal outcomes following single frozen blastocyst transfer

AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles

Contact Info

Product

Resources

About